Eli Lilly & Co. Q3 2024 10-Q Summary
Business Context and Reporting Period
This Form 10-Q covers the quarterly period ended September 30, 2024. Eli Lilly and Company operates as a single segment engaged in the discovery, development, manufacturing, and marketing of pharmaceutical products globally. The company is a large accelerated filer with approximately 949 million shares of common stock outstanding as of October 25, 2024.
Key Financial Metrics
| Metric | Q3 2024 | Q3 2023 | YTD 9M 2024 | YTD 9M 2023 |
|---|---|---|---|---|
| Revenue | $11,439.1M | $9,498.6M | $31,509.9M | $24,770.7M |
| Net Income | $970.3M | $(57.4M) | $6,180.2M | $3,050.7M |
| Diluted EPS | $1.07 | $(0.06) | $6.83 | $3.38 |
| Gross Margin % | 81.0% | 80.4% | 80.9% | 78.6% |
| Operating Cash Flow (9M) | $6,344.1M (2024) vs $4,552.0M (2023) | |||
| Total Debt | $31.12B (Sep 30, 2024) vs $25.23B (Dec 31, 2023) | |||
| Cash & Equivalents | $3.37B (Sep 30, 2024) vs $2.82B (Dec 31, 2023) |
Material Changes vs. Prior Period
- Revenue Growth: Revenue increased 20% in Q3 and 27% YTD, driven primarily by volume growth in Mounjaro (tirzepatide), Zepbound (tirzepatide), and Verzenio. This was partially offset by declines in Trulicity and the absence of one-time revenue from the 2023 sale of the olanzapine portfolio (Zyprexa).
- Profitability: Net income turned positive in Q3 2024 ($970.3M) compared to a loss in Q3 2023, driven by higher gross margins. However, results were impacted by significant non-cash charges.
- Acquired IPR&D: The company recorded $2.83 billion in acquired in-process research and development (IPR&D) charges in Q3 2024, primarily related to the acquisition of Morphic Holding, Inc. ($2.55 billion charge). This significantly impacted the effective tax rate (38.9% in Q3 2024 vs. 113.4% in Q3 2023).
- Debt Issuance: Total debt increased by $5.89 billion year-over-year due to the issuance of $11.46 billion in fixed-rate notes in February and August 2024 to fund acquisitions (Morphic) and general business purposes.
Guidance, Outlook, and Risks
- Supply Chain: Demand for incretin medicines (Mounjaro/Zepbound) remains high. The company projects that supply will meet near-term U.S. demand, but global sales growth remains a function of production capacity. The company is expanding manufacturing capacity over the next several years.
- Regulatory & Pricing: The Inflation Reduction Act (IRA) poses pricing risks. Jardiance was selected for government price negotiation effective 2026, with a 66% discount announced. The company expects additional products to be selected in future years.
- Legal Proceedings: Significant ongoing litigation includes product liability claims related to Mounjaro and Trulicity, patent disputes regarding Emgality, and various pricing investigations (340B program, insulin pricing). The company believes the resolution of these matters will not have a material adverse effect on its financial position but could impact results in any single period.
- Counterfeit Products: The company notes an increase in counterfeit and compounded incretins, which it views as a patient safety risk and intends to address legally.
Key Investor Verification Points
- Supply Constraints: Verify the timeline for new manufacturing capacity to ensure it aligns with projected demand for tirzepatide products.
- Acquisition Integration: Monitor the commercialization progress of Morphic's assets (MORF-057) following the $2.67 billion acquisition.
- IRA Impact: Track future HHS selections for price negotiation under the IRA and the resulting revenue erosion for key products.
- Legal Exposure: Review updates on the Mounjaro/Trulicity product liability multidistrict litigation and the outcome of the Emgality patent appeal.
- Debt Servicing: Assess the impact of increased interest expense on future earnings given the $31.1 billion debt load.